8/12/2019 Aplastic Anemia(KBK)
1/24
APLASTIC ANEMIA
Dairion Gatot, Soegiarto GaniDivisi Hematologi-Onkologi Medik
Departemen Ilmu Penyakit Dalam FK-USU/RS H.Adam Malik
Medan 2008
8/12/2019 Aplastic Anemia(KBK)
2/24
DEFINITION
Pancytopenia with markedly hypocellular marrow
Incidence world wide: 2-5 cases/million population/year
Severe aplastic anemia =
marrow of less than 25 % celularity or less than 50 %
hemopoietic cells, with at least two of the following:
- Absolute neutrophil count less than 500/l
- Platelet count of less tan 20.000/l- Corrected reticulocyte index of less than 1
8/12/2019 Aplastic Anemia(KBK)
3/24
PATHOGENESIS
* Mechanism of pathogenesis
- Intrinsic stem cell defect
- Failure of stromal microenvironment
- Growth factor defect or deficiency- Immune suppression of marrow
8/12/2019 Aplastic Anemia(KBK)
4/24
Etiologic classification
* Acquired
- Chemicals
- Drugs (eq: Chloramphenicol, cytotoxic chemotherapy)- Radiation
- Viruses (eq: Parvovirus B19, hepatitis virus, HIV)
- Miscellaneous
ETIOLOGY
8/12/2019 Aplastic Anemia(KBK)
5/24
Etiologic classification* Hereditary
- Fanconi Anemia
- Autosomal recessive (FA-A to FA-H)
- Abnormal skin pegmentation
- Chromosom fragility
- Dyskeratosis congenital may evolve into aplastic anemia
- Schwachman - Diamond syndrome
* Idiopathic
ETIOLOGY
8/12/2019 Aplastic Anemia(KBK)
6/24
Pathogenesis
Damage induced by chemicals, drugs,
viruses, or antigenslymphocyte
activation (eq: IFN)
apoptotic death ofhematopoietic cells in the bone marrow
8/12/2019 Aplastic Anemia(KBK)
7/24
CLINICAL FEATURES
Fatigue, bleeding, or infections as a consequence
of cytopenias
Physical examination:signs of anemia, bleeding, or infection.
8/12/2019 Aplastic Anemia(KBK)
8/24
LABORATORY FEATURES
* Pancytopenia
* Low reticulocyte index; red cells may be macrocytic
* Markedly hypocellular marrow* Absolute neutrophil count low
* Abnormal cytogenetic findings suggest hypoplastic
myelodysplastic syndrome rather than aplastic anemia
* Negative sucrose hemolysis test to rule out PNH
8/12/2019 Aplastic Anemia(KBK)
9/24
DIFFERENTIAL DIAGNOSIS OF
PANCYTOPENIA & HYPOPLASTIC MARROW
* Hypoplastic myelodysplastic syndrome
* Paroxysmal nocturnal hemoglobinuria
* Hypoplastic acute lymphocytic leukemia
* Hairy cell leukemia
8/12/2019 Aplastic Anemia(KBK)
10/24
1. BMP and biopsyfor the determination of cellularity and exclusion of other diseases
The presence of blasts or abundant megakaryocytes is not
compatible with the diagnosis of AA
2. Elevation of transaminasesAA/ hepatitis syndrome
3. HLA-typingcandidate for allogeneic bone marrow transplantation
HLA-DR*15 in AA and (PNH) and may constitute
a positive prognostic factor with regard to IS therapy
Diagnostic considerations
8/12/2019 Aplastic Anemia(KBK)
11/24
4. Flow cytometric
-Analysis of red cells and granulocytes should be performed to
establish the presence of a PNH clone.-Flow cytometric distinction between normal and PNH phenotypes
5. Several novel testsin assessment of immune responsiveness
example : flow cytometric determination of IFN- expression,
Serum levels of these cytokines.
response to IS
8/12/2019 Aplastic Anemia(KBK)
12/24
Table 1. Classification of aplastic anemia by counts.
Severe AA
ANC < 500/ul
ARC < 40,000/ul in anemic
/tranfusion-dependent patients
Platelets < 20 x 103 /ul
2 out of 3 criteria
Moderate AA
AA not fulfilling severity criteria
a diagnosis of chronic MAA
requires persistent moderately
depressed counts > 3 months
Abbreviations: ANC, absolute neutrophil count; ARC, absolute reticulocyte count;
MAA, moderate AA
Jaroslaw P. Maciejewski and Antonio M . Risitano
American Society of Hematology 2005
8/12/2019 Aplastic Anemia(KBK)
13/24
CLINICAL COURSE
Median survival of untreated severe
aplastic anemia is 3 to 6 months
(20 % survive longer than 1 year)
8/12/2019 Aplastic Anemia(KBK)
14/24
TREATMENT
* Marrow transplantation is curative
* Indicated in patients less than 40 years of age with and
HLA-related matched or 1 antigen mismatched donor
* Only One-third of patients have a suitable donor
* 75 to 85 % of previously untransfused patients achieve
cure with appropriate donor
* 55 to 60 % of multiply transfused patients achieve
cure with appropriate donor* 94% The overall survival.
* Immunosupressive therapy : not curative
8/12/2019 Aplastic Anemia(KBK)
15/24
TREATMENT
* Immunosupressive therapy : not curative
* Antithymocyte globulin (ATG)
- 50 % response rate
- dose : 15 to 40 mg/kg intravenously for 4 to 10 days
- fever, chills common on first day of treatment
- accelerated platelet destruction with
thrombocytopenia frequent
- serum sickness common with fever, rash & arthralgias
occurring 7 to 10 days after beginning treatment
8/12/2019 Aplastic Anemia(KBK)
16/24
TREATMENT
* Cyclosporine (CSP)
- primary treatment or in patients refractory to ATG
- dose: 3 to 7 mg/kg daily orally for at least 4 to 6
months- dose adjusted to maintain proper blood levels
- renal impairment common side effect
- response rate 25 % ( range of response is 0 to 80 %)
8/12/2019 Aplastic Anemia(KBK)
17/24
TREATMENT
* Combinations
-ATG and CSP may yield an improved response rate
as high as 57 % of patients
- long term sequelae of immunosupressive therapy
after 8 years such as :
- recurrent aplasia
- PNH
- acute myelogenous leukemia
- myelodysplastic syndrome
8/12/2019 Aplastic Anemia(KBK)
18/24
TREATMENT
* Androgen as primary therapy has not been efficacious
in severe or moderate aplastic anemia
* Hemopoietic growth factors have been used to treat
neutropenia- Temporary improvement in neutrophil count has been
observed with GM-CSF or G-CSF treatment
* G-CSF + Combination with an ATG/CsA regimen,
- Improve neutropenia and response to this therapy constitutesan early positive prognostic factor
8/12/2019 Aplastic Anemia(KBK)
19/24
TREATMENT
* Supportive Care
- Immediate HLA typing of patient and siblings as
possible marrow donors
- Minimal or no transfusions in potential transplant
recipients- If transfusions are needed, do not use family donors in
a potential transplant recipients
- Transfuse platelets based on assessment of risk of
bleeding and not solely on platelet count- Single donor platelets should be used to minimize HLA
sensitization and subsequent refractoriness
8/12/2019 Aplastic Anemia(KBK)
20/24
TREATMENT
Supportive Care
- Leukocyte-depleted blood products reduce sensitization
- Transfuse packed RBCs when Hb < 7 to 8 g/dl
- Obtain CMV serology for prospective transplant recipients- Neutropatic precautions for hospitalized patients with
absolute neutrophill counts of less than 500
- Prompt institution of board spectrum IV antibiotics for
fever after appropriate cultures have been obtained.
8/12/2019 Aplastic Anemia(KBK)
21/24
Protocol Therapy :Conservative therapies
Immunosuppression (IS)
1. Horse (ATGam at 20 mg/kg per day for 4 days)
2. Rabbit ATG (Thymoglobulin at 3.5 mg/kg per day for 5 days)
Horse ATGResponse rate 70-80 %5 y Survival 80-90%
3. CsA (12-15mg/kg in a divided dose bid) given usually for 6 months
4. Steroidscounteract the serum sickness ATG therapy
5. G-CSFmay improve neutropenia but does not increase survival
Jaroslaw P. Maciejewski and Antonio M . Risitano
American Society of Hematology 2005
8/12/2019 Aplastic Anemia(KBK)
22/24
Respon criteria :Was defined improvement of blood count
(complete or partial) within 4 months.
Complete Remission (CR):
1. Haemoglobin (Hb) level was normal for the
patient age
2. Neutrophil >1,5 x 10.9/l
3. Platelet >150 X 10.0/L
8/12/2019 Aplastic Anemia(KBK)
23/24
Partial Remission (PR) :
transfusion independence and
an unsupported increase in counts at least one
cell line over the baseline value:
Hb level by at least 3 g/dl,
Neutrophil by at least 0,5 x 109/l,If previously lower than 0,5 x 109/l,
Platelet by at least 20 X 109/L,
If previous lower than 20 X 109/L,
or by doubling, or normalization of counts
of at least one cell line
if previous counts of the respective cell line(s)
did not meet the criteria for SAA
8/12/2019 Aplastic Anemia(KBK)
24/24